Morpholino oligonucleotide solutions for research & therapeutics
GenElixir® is founded by scientists and healthcare professionals with a three pillar vision: discover next-generation morpholino chemistry, manufacture it at scale, and partner with the world's drug developers.
GenElixir® manufactures and supplies high-purity PMOs, morpholino monomers, and our proprietary self-transfecting GMO-PMO chimera — protected by two US patents. Universities, CDMOs, and drug discovery teams worldwide order from our catalog and ship within days from Visakhapatnam or West Berlin, NJ — at a 40–60% cost advantage over Western peers.
From university research labs to biotech CDMOs — GenElixir delivers research-grade morpholino chemistry with the precision your science demands and the speed your timelines require.
The sole manufacturer of PMO monomers and GMO-PMO chimeras in India, giving domestic researchers direct access at significantly lower cost than US or EU alternatives.
Our patented self-transfecting GMO-PMO chimeras eliminate the need for viral vectors, electroporation, or lipid transfection reagents — reducing experimental complexity.
Manufacturing in India with a fully in-house synthesis and QC pipeline delivers internationally comparable purity at significantly lower cost than leading global suppliers.
Every batch is HPLC-tested in our Visakhapatnam facility. Certificates of analysis confirm ≥95% purity for monomers, ensuring confident synthesis from the first step.
Dramatically faster than the 2–4 week lead times from US or China-based suppliers, keeping your research timelines on track and your experiments moving.
Our synthetic chemists provide expert guidance on sequence selection, modification chemistry, and experimental design. Custom synthesis to exact specifications.
Two top-level categories mirroring your workflow: Category MO for research-ready, sequence-specific antisense reagents, and Category MM for in-house PMO synthesis building blocks.
Complete product specifications, chemical structures, CAS numbers, molecular formulas, and ordering guidance for all MO oligomers and MM monomers — formatted for offline reference and procurement.
Custom PMO & GMO-PMO chimera · 5′ modifications · 250–500+ nmol
Patent-protected self-transfecting morpholino oligomers
4 sub-families: SMMT · SMMF · CMMT · CMMF
PMOs of 20–30 nucleotides bind target mRNA with high sequence specificity via Watson-Crick base pairing. The non-ionic phosphorodiamidate backbone confers nuclease stability and minimal off-target effects. Four FDA-approved drugs — eteplirsen, golodirsen, viltolarsen, casimersen — are PMO-based.
Functional chemistry handles at the 5′ terminus for attachment of fluorescent labels, drugs, peptides, or PEG spacers via Click, Michael addition, or amide coupling reactions.
| Catalog No. | Modification | Chemistry | Application |
|---|---|---|---|
| GILPMO302 | 5′-Alkyne-Serine | Click · CuAAC / SPAAC | Bioconjugation with azide-bearing payloads (dyes, PEG, targeting ligands, solid surfaces) |
| GILPMO303 | 5′-TEG-Cysteine | Thiol-Maleimide | Michael addition via TEG spacer. Improved aqueous solubility. SCPh₃-protected thiol. |
| GILPMO304 | 5′-DEG-Cysteine | Thiol-Maleimide | Compact DEG spacer variant. Preferred when close payload proximity is required. |
| GILPMO305 | 5′-Triethylene Glycol (TEG) | Neutral Spacer | Non-reactive PEG-like tail. Improves solubility and PK profile. Suited to in vivo / zebrafish studies. |
Standard 250 / 400 / 500 nmol · multiples of 200 nmol above 500 · 5′ modifications available · gram-scale from 2027
Self-transfecting morpholino chemistry · proprietary to GenElixir®
The GMO-PMO chimera integrates guanidinium-functionalized morpholino (GMO) units into a PMO backbone. The guanidinium groups facilitate direct cellular uptake, eliminating lipofection, electroporation, or viral delivery. In sequence notation, lowercase 'g' denotes guanidinium-modified residues.
Custom sequence + scrambled control · 250 / 400 / 500 nmol · guanidinium modification included
| Code | Sub-Family | Catalog Range | Protecting Group | Activation | Purity | Storage | Shelf Life |
|---|---|---|---|---|---|---|---|
| SMMT | Trityl-Protected Standard Monomers | GILSMMT001–004 | Trityl | Standard | ≥95% | 4°C | 2 years |
| SMMF | Fmoc-Protected Standard Monomers | GILSMMF001–004 | Fmoc | Standard | ≥95% | 4°C | 2 years |
| CMMT | Trityl-Protected CPA Monomers (Activated) | GILCMMT001–004 | Trityl | Chlorophosphoramidate | ≥95% | −20°C | 6 months |
| CMMF | Fmoc-Protected CPA Monomers (Activated) | GILCMMF001–004 | Fmoc | Chlorophosphoramidate | ≥95–98% | −20°C | 12 months |
Six-membered morpholine ring bearing the nucleobase and N-trityl protecting group. Intermediate in multi-step PMO synthesis and building block for solution-phase assembly.
Morpholine ring with Fmoc (9-fluorenylmethyloxycarbonyl) protecting group. Used in Fmoc-based PMO synthesis protocols.
The 3′ chlorophosphoramidate group enables condensation during solid-phase PMO synthesis — direct building blocks consumed by automated PMO synthesizers. Storage at −20°C; 6-month shelf life.
Fmoc-variant of the activated CPA monomer set for Fmoc-based PMO synthesis protocols. Note the 12-month shelf life (longer than CMMT) and ≥95% purity specification (G base at ≥95%). Storage at −20°C.
All 4 sub-families · minimum 1g order · ships within 2 business days (India) · contact us for current pricing
PMOs are next-generation antisense agents with an unmatched biological profile for gene silencing, splice correction, and therapeutic development.
Phosphorodiamidate Morpholino Oligonucleotides (PMOs) are synthetic, sequence-specific antisense agents. The morpholine ring replaces the natural ribose sugar, and phosphorodiamidate linkages replace the charged phosphodiester backbone. This non-ionic backbone is the key to their superior pharmacological profile.
PMOs of 20–30 nucleotides bind their complementary mRNA targets with high specificity, blocking translation or correcting aberrant splicing. They are nuclease-resistant, water-soluble, and exhibit minimal off-target and immune-stimulatory effects.
The therapeutic power of PMOs is proven: four FDA-approved drugs for Duchenne Muscular Dystrophy are PMO-based, demonstrating the clinical viability of this chemistry in rare disease treatment.
Ref: Summerton JE. Current Topics in Medicinal Chemistry, 2007, 7, 651–660
Compared to siRNA, PNA, and S-DNA, morpholinos offer a uniquely favorable profile for research and therapeutic development.
Fully water-soluble for easy formulation in aqueous buffers — no organic co-solvents needed.
Binds target mRNA with high specificity via Watson-Crick base pairing, minimizing off-target effects.
Minimal non-antisense activity — reduces experimental noise and improves result interpretability.
Excellent safety profile in cell culture and in vivo. Non-toxic to mammalian cells at effective doses.
Highly resistant to nuclease degradation — active in complex biological matrices including serum.
Sustained knockdown activity over extended periods — fewer dosing events for in vivo studies.
Validated in zebrafish, mouse, and human models. Clinically proven in four FDA-approved drugs.
Thermodynamically predictable binding — enables rational sequence design with standard tools.
The science behind GenElixir products is validated through peer-reviewed publications in leading journals including Nature Communications, Molecular Therapy, Journal of Organic Chemistry, and Bioconjugate Chemistry.
Foundational paper demonstrating the first automated synthesis of PMOs using both Trityl and Fmoc-protected chlorophosphoramidate monomers on a standard DNA synthesizer. Established the chemistry underlying GenElixir's SMMT, SMMF, CMMT, and CMMF monomer product lines. Showed that ETT and iodine are suitable coupling reagents for efficient PMO assembly.
Reports the complete solid-phase synthesis of Casimersen (Amondys 45), one of four FDA-approved PMO drugs for Duchenne Muscular Dystrophy, along with novel 3′-end modifications designed to improve therapeutic properties. Demonstrates GenElixir's capability to synthesize clinically validated PMO sequences.
Introduces the 5′-thiol functionalized PMO synthesis using an optimized cysteine-derived linker — the chemistry behind GenElixir's TEG-Cysteine and DEG-Cysteine end modifications. The thiol handle enabled conjugation with an internal guanidinium transporter (IGT) peptide, significantly improving cellular delivery and NANOG knockdown in MCF7 breast cancer cells.
Describes a novel class of self-permeable PMO carrying C5-guanidino-functionalized pyrimidine bases at the 5′ terminus — an alternative GMO-PMO architecture where the guanidinium groups are attached to the nucleobases rather than the backbone. Successfully downregulated Sox2 in the aggressive triple-negative breast cancer cell line MDA-MB-231.
The landmark GMO-PMO chimera publication and GenElixir's core patent validation study. Demonstrated that GMO-PMO chimeras targeting NANOG enter cells autonomously, silence the EMT and stemness pathway in MCF7 cells, produce expected phenotypes in zebrafish even after 16-cell stage delivery, and suppress 4T1 mammary carcinoma allografts in BALB/c mice with restoration of organ histopathology.
Extends GMO-PMO chimera technology into immuno-oncology. The chimera targeting PD-L1 mRNA inhibits immune checkpoint expression in multiple breast cancer cell lines (MDA-MB-231, MDA-MB-468) and potentiates antitumor T-cell immunity using Jurkat E6.1 lymphoblasts. In vivo efficacy confirmed in BALB/c mice — positioning GMO-PMO as a potential alternative to anti-PD-L1 antibody immunotherapy.
Independent validation of GMO-PMO chimera technology in a gut microbiome and cholesterol metabolism context. GMO-PMO was used to knock down AUF-1 in mice, revealing that AUF-1 is required for butyrate-driven cholesterol reduction via the Dicer-1/miR-122 axis. Demonstrates the chimera's in vivo delivery and gene silencing in a non-oncology disease model.
GMO-PMO chimera used as the gene silencing tool in an atherosclerosis study. Hepatic GSTM3 knockdown in Apoe-knockout mice demonstrated that GSTM3 deficiency accelerates plaque formation through mitochondrial redox dysfunction and necroinflammation — validating the chimera's efficacy in cardiovascular disease research models.
Highest-impact publication. Collaboration with Prof. Erez Raz (University of Münster / Max Planck). Developed a light-activated system where UV irradiation uncages a GMO-PMO chimera that displaces an antisense morpholino from target mRNA, enabling spatiotemporal control of protein expression in live zebrafish embryos. The cell-permeable GMO-PMO chimera was produced using a mercury-free solid-phase approach.
Phosphorodiamidate Morpholino Oligonucleotides and GMO-PMO chimeras enable a wide range of research workflows. Below are the most common research applications and which GenElixir products are best suited to each.
PMOs block the AUG start codon or 5′UTR of target mRNA to prevent ribosomal binding and translation, achieving selective knockdown of target gene expression without RNase H or RISC machinery.
→ Recommended: Custom PMO (PMO · GILPMO301-T)PMOs targeting splice donor or acceptor sites can force exon skipping or inclusion — the mechanism behind FDA-approved DMD drugs eteplirsen, golodirsen, casimersen, and viltolarsen.
→ Recommended: Custom PMO with sequence-optimized targetingThe gold-standard reagent for zebrafish gene knockdown studies. PMOs are microinjected into 1–4 cell stage embryos for stable, predictable phenotypic analysis through early development.
→ Recommended: Standard 25-mer Custom PMOPatented GMO-PMO chimera enters mammalian cells autonomously — eliminating lipofection, electroporation, and viral vectors. Reduces toxicity and dosing complexity compared to Vivo-Morpholinos.
→ Recommended: Custom GMO-PMO Chimera (GMO · GILGMO401)BODIPY-labelled PMOs enable real-time fluorescence imaging of oligo uptake and subcellular distribution (λex 498 nm, ε = 79,000 cm⁻¹ M⁻¹).
→ Recommended: 3′-BODIPY end modificationAlkyne-Serine handles enable CuAAC/SPAAC click conjugation with azide-bearing payloads. TEG/DEG-Cysteine handles enable thiol-maleimide conjugation for antibody-PMO and polymer-PMO constructs.
→ Recommended: 3′ or 5′ Alkyne-Serine / TEG-Cysteine modsTrityl-protected (MM1) and chlorophosphoramidate (MM2) morpholino monomers for all four nucleobases enable in-house solid-phase PMO assembly on standard oligonucleotide synthesizers.
→ Recommended: Category MM monomers (1g+ minimum)PMOs are the dominant chemistry class for Duchenne Muscular Dystrophy research and other rare diseases involving aberrant splicing or undesired protein expression — backed by four FDA approvals.
→ Recommended: Custom sequence PMO + scrambled controlGenElixir supplies morpholino reagents to four primary customer segments across India and worldwide — from individual academic labs to large pharmaceutical R&D pipelines.
Principal investigators in molecular biology, developmental biology, gene therapy, and rare disease research. Special academic pricing for funded research projects.
Antisense and gene therapy program teams sourcing PMO reagents and custom oligomers for preclinical development of rare disease and splice-correction therapeutics.
Contract research and contract manufacturing organizations expanding into oligonucleotide services — sourcing morpholino monomers, custom oligos, and gram-scale PMO supply.
Publicly funded research labs working on genetic disorders, DMD, and rare disease therapeutics. Procurement support for DBT, CSIR, and ICMR-funded projects.
India's only PMO manufacturer delivers capabilities previously available only from US and China — at substantially better economics and timelines.
| Capability | GenElixir® |
Gene Tools (US) | Hongene (CN/US) | BOC Sciences (US) | Biosynth (CH) | WuXi AppTec (CN) |
|---|---|---|---|---|---|---|
| India-based manufacturing | ✓ Only one | — None | — None | — None | — None | — None |
| Cost vs US/EU baseline | ✓ 40–60% lower | Base price | ~ Moderate | ~ Moderate | Base price | ~ Moderate |
| GMO-PMO chimera (patented) | ✓ Proprietary | — No | — No | — No | — No | — No |
| Custom PMO oligomers | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Morpholino monomers | ✓ Full MM1+MM2 | ~ Limited | ✓ | ~ Limited | ✓ | ~ Via CDMO |
| India delivery speed | ✓ 5 business days | 1–2 weeks | 2–4 weeks | 2–4 weeks | 2–3 weeks | 2–4 weeks |
| End mods (BODIPY, Click, TEG) | ✓ Full range | ✓ Vivo-Morpholinos | ~ Partial | ~ Partial | ~ Partial | ✓ CDMO |
| Gram-scale CDMO | ✓ via partnership 2027 | ~ Limited | ✓ | — No | ~ Limited | ✓ GMP |
| In-house HPLC QC | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Self-transfecting tech | ✓ GMO-PMO chimera | Vivo (dendrimer) | — No | — No | — No | — No |
Comparison data compiled from publicly available product catalogs and pricing references as of June 2026. Sources: gene-tools.com, hongene.com, bocsci.com, biosynth.com, wuxiapptec.com. Additional PMO market participants include Sarepta Therapeutics (PMO/PPMO therapeutic drugs only — not reagent supplier), Amerigo Scientific (US, limited monomer catalog), Asymchem (China, contract manufacturing), Nitto Denko Avecia (US, GMP oligo CDMO), and The Morpholino Group / IACS Kolkata (academic R&D laboratory, not commercial supplier).
Our pioneering work in PMO-based therapeutics has attracted recognition from government, industry, and the academic community.
Dr. Jitendra Singh, Union Minister for Department of Science and Technology, Government of India, visited the GenElixir booth during his official visit to Kolkata — recognizing GenElixir's pioneering role in India's antisense therapeutics landscape.
GenElixir presented our GMO-PMO chimera technology at the 2025 Nucleic Acid Therapeutics Meeting at JNCASR Bengaluru — engaging directly with India's leading nucleic acid research community.
"We provide custom-designed antisense PMOs, cell-permeable GMO-PMO chimeras, Morpholino monomers, linkers, loading monomers, and various other functionalized monomers — enabling the manufacturing and discovery of antisense-based medicines."
No minimum contract, no platform lock-in. Order what you need when you need it, with responsive scientific support throughout.
Min. 1g · Ships 2 days · Call for quote
Select your catalog number (GILSMMT/SMMF/CMMT/CMMF 001–004) from the product table
Specify quantity in grams (minimum 1 gram per order)
Indicate if HPLC certificate of analysis is required (additional cost)
Send your order to sales@genelixir.com — our team responds within 1 business day. Monomers ship within 2 business days (India)
250 nmol minimum · Pricing on inquiry
Specify product type: Standard PMO or GMO-PMO Chimera
Provide your 5′→3′ nucleotide sequence (lowercase 'g' for GMO residues)
Select quantity: 250 / 400 / 500 nmol — or specify larger amount
Specify end modifications (BODIPY, Click, TEG/DEG spacers) if required
Email sales@genelixir.com — formal quotation within 2 business days
Our chemistry team is available for pre-order technical consultation — sequence design, modification strategy, experimental planning, and scale-up discussion.
Direct answers to the questions our customers, AI assistants, and procurement teams most often ask about Phosphorodiamidate Morpholino Oligonucleotides, GMO-PMO chimera technology, and ordering from GenElixir.
eteplirsen, golodirsen, viltolarsen, and casimersen — are PMO-based.sales@genelixir.com or call +91 897 773 4216.sales@genelixir.com — formal quotation within 2 business daysOur team is ready to support your research with high-quality products, technical expertise, and reliable service you can count on.